JavaScript is disabled. Please enable to continue!
Services >> In Vitro Pharmacology >> PDEs

Discover the next selective PDE inhibitor

Sidebar Image

Cyclic nucleotide phosphodiesterases (PDEs) are ubiquitously distributed throughout mammalian tissues and play a major role in cell signaling by hydrolyzing cAMP and/or cGMP. Due to their diversity and specific distribution at the cellular and subcellular levels, PDEs are able to selectively regulate various cellular functions. This regulatory ability implicates PDEs in various therapeutic areas including CNS, inflammation, and oncology. 

As PDEs are expressed in a variety of tissues, selectivity is a prerequisite for a therapeutically viable PDE inhibitor. For example, high selectivity for PDE5 inhibitors is important for treating erectile dysfunction while minimizing possible side effects associated with inhibition of other PDEs. These possible side effects include tachycardia and vasodilation that are attributed to inhibition of PDE1 and PDE3, or blue-green vision disturbances that are attributed to inhibition of PDE6.

In order to meet the growing need for robust PDE profiling, Eurofins, through the expertise of Cerep and Panlabs, has designed an HTS platform to determine the inhibitory effects and selectivity of compounds on the PDE superfamily.

Advantages of PDE Profiling with Eurofins:

  • Robustness and reproducibility confirmed by screening a broad panel of commercial available reference inhibitors and known commercial drugs
  • Radiometric assays for high quality enzymatic assays
  • Choose from over 20 PDEs, covering PDE1-11